Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients

Cerebrovascular Diseases

Volumn 25, Issue 5, 2008, Pages 450-456

  Gan, Robert ^a,f   Lambert, Caroline ^a   Lianting, Jiao ^c   Chan, Edwin S Y ^a   Venketasubramanian, N ^a   Chen, Christopher ^a   Chan, Bernard P L ^b   Meyer Samama, Michel ^d   Bousser, Marie Germaine ^e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d HÔTEL DIEU   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

Danqi Piantan Jiaonang, stroke; Safety studies; Traditional Chinese medicine

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHINESE DRUG; CREATININE; D DIMER; DANQI PIANTAN JIAONANG; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GLUCOSE; NEUROAID; NITRATE; ORAL ANTIDIABETIC AGENT; POTASSIUM;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; BLOOD ANALYSIS; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; ERYTHROCYTE COUNT; ERYTHROCYTE VOLUME; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMATOLOGY; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE COUNT; LONG TERM EXPOSURE; MALE; MEDICAL PARAMETERS; MONOTHERAPY; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ADMINISTRATION, ORAL; ADULT; AGED; ASPIRIN; CAPSULES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; FEMALE; HEMORHEOLOGY; HEMOSTASIS; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; STROKE;

EID: 44449155927     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000126919     Document Type: Article

References (11)

1. World Health Organization: The World Health Report 2004: Changing History. Geneva, World Health Organization, 2004.
2. Strong K, Mathers C, Bonita R: Preventing stroke: saving lives around the world. Lancet Neurol 2007;6:182-187.
3. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E: Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003;3:CD000213.
4. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R: Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 2000;31:1240-1249.
5. Stroke Unit Trialists' Collaboration: Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2002;1:CD000197.
6. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW: 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-477.
7. Registry review shows many factors hinder acute stroke care. AHA rapid access journal report. Stroke journal report, 12 May 2005.
8. Wu B, Liu M, Liu H, Li W, Tan S, Zhang S, Fang Y: Meta-analysis of traditional Chinese patent medicine for ischemic stroke. Stroke 2007;38:1973-1979.
9. Feigin VL: Herbal medicine in stroke. Does it have a future? Stroke 2007;38:1734-1736.
10. Adams JD, Wang R, Yang J, Lien EJ: Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chin Med 2006;1:3.
11. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.